Table: Santen Pharm -Q1 group results (IFRS)
06/08/2026 07:34
Aug 6 (Reuters)-
Santen Pharmaceutical Co Ltd
CONSOLIDATED FINANCIAL HIGHLIGHTS
(in billions of yen unless specified)
3 months ended 3 months ended Year to
Jun 30, 2026 Jun 30, 2025 Mar 31, 2027
LATEST YEAR-AGO COMPANY
RESULTS RESULT FORECAST
Sales 68.96 68.74 311.00
(+0.3 pct) (-8.1 pct) (+6.6 pct)
Operating 8.12 7.57 49.50
(+7.2 pct) (-42.4 pct) (+3.6 pct)
Pretax
Net 7.19 5.88 40.00
(+22.4 pct) (-44.7 pct) (+7.0 pct)
EPS Basic 22.38 yen 17.32 yen 124.42 yen
EPS Diluted 22.30 yen 17.28 yen
Ann Div 38.00 yen 42.00 yen
-Q2 Div 19.00 yen 21.00 yen
-Q4 Div 19.00 yen 21.00 yen
NOTE - Santen Pharmaceutical Co Ltd.
(Figures are reported based on international accounting rules (IFRS).)
If there is no Q1 or Q3 dividend, Q2 will in most cases correspond to the first-half
dividend and Q4 to the second-half dividend announced before a new corporate law in
2006 allowed companies to pay and report dividends on a quarterly basis.
*Net - represents Net profit attributable to owners of the parent company.
To see Company Overview page, click reuters://REALTIME/verb=CompanyData/ric=4536.T